Question to the Department of Health and Social Care:

To ask Her Majesty's Government whether new biomarker-linked treatments for glioblastoma multiforme would be considered candidate technologies for the Accelerated Access Pathway under the Accelerated Access Review.

As set out in the response to the Accelerated Access Review, the Accelerated Access Pathway (AAP) will focus on affordable products which can dramatically improve efficiency, fill an unmet need or make a step change in patient outcomes.

There are no restrictions on what type of products the AAP should focus on. The AAP will be launched shortly after the next meeting of the Accelerated Access Collaborative.